The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000780358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
13/05/2026
Date registered
Help: Date registered
30/06/2026
Date last updated
Help: Date last updated
18/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
30/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A Phase 1 Study in Healthy Adult Participants to Evaluate the Bioavailability of GRWD5769 Tablets Relative to Capsules and the Effect of Food
Scientific title
A Phase 1 Study in Healthy Adult Participants to Evaluate the Bioavailability of GRWD5769 Tablets Relative to Capsules and the Effect of Food
Additional trial identifiers [1] 317233 0
GRWD5769-HV-01
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Cancer 343425 0
Condition category
Condition code
Cancer 339513 339513 0 0
Any cancer

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
There will be up to 3 parts conducted in the study, Part A1, A2, and Part B.

Part A1 will look at bioavailability of 800mg GRWD5769 in the fasted state.
Part A2 will look at bioavailability of 400mg GRWD5769 in the fed and fasted state, but is optional, and will only be conducted if recommended to the sponsor by the study scientific review committee after review of Part A1.
Part B will look at food-effect.

The intervention for each Part consists of a 14-day screening period, followed by Treatment Period 1, Washout period, Treatment Period 2, and then an End of Treatment visit. Participants will be admitted and remain at the research unit for the entirety of each Treatment Period (5-6 days). Dosing occurs after eligibility confirmation and randomization.

Healthy participants will be administered GRWD5769 as a single 800 mg dose to evaluate the bioavailability of a GRWD5769 tablet formulation relative to a GRWD5769 capsule formulation; if these 2 formulations are determined not to be comparable at an 800mg dose (Part A1), the bioavailability of a GRWD5769 tablet formulation relative to a GRWD5769 capsule formulation will be re-evaluated at a 400mg dose (Part A2).

A Safety Review Committee will review available safety/PK data for Part A1 and make recommendations regarding the GRWD5769 formulation and dose for a food-effect evaluation (Part B).

Part A:
Please note that this Part is fasted.
GRWD5769 is to be administered once orally, with a full cup (250 mL) of non-carbonated, room temperature water.
Participants must fast for 2 hours prior to, and for 1 hour following each dose of GRWD5769 (water is permitted).

Part A1
a) an 800mg dose of GRWD5769 will be provided
b) This Part consists of two different arms: (1) the Film Coated Tablet Formulation and (2) the Capsule Formulation.
Approximately 18 participants will be randomised in a ratio of 1:1 to receive both treatment formulations in one of 2 treatment sequences:

Sequence 1:
Treatment Period 1: 4 x 200 mg GRWD5769 capsules in the fasted state followed by
Treatment Period 2: 2 x 400mg GRWD5769 tablets in the fasted state

Sequence 2:
Treatment Period 1: 2 x 400mg GRWD5769 tablets in the fasted state followed by
Treatment Period 2: 4 x 200 mg GRWD5769 capsules in the fasted state

c) There is a minimum 48 hour 'wash out' period between Treatment Period 1 and Treatment Period 2
d) Participants will be observed when dosing to ensure adherence to dosage requirements.

Part A2 (Optional)
This Part would commence if the 2 formulations above are determined not to be comparable at an 800 mg dose, the bioavailability of a GRWD5769 Film Coated Tablet Formulation relative to a GRWD5769 Capsule Formulation will be re-evaluated at a 400 mg dose. A Safety Review Committee (SRC) will make recommendations to the Sponsor regarding GRWD5769 formulation and dose for food-effect evaluation:

a) a 400mg dose of GRWD5769 will be provided:

Sequence 1:
Treatment Period 1: 2 x 200 mg GRWD5769 capsules in the fed or fasted state followed by
Treatment Period 2: 1 x 400mg GRWD5769 tablets in the fed or fasted state.

Sequence 2:
Treatment Period 1: 1 x 400mg GRWD5769 tablets in the fed or fasted state followed by
Treatment Period 2: 2 x 200 mg GRWD5769 capsules in the fed or fasted state.

b) Participants will be observed when dosing to ensure adherence to dosage requirements.

Part B:
Participants in the fed state will receive a high calorie/high fat breakfast according to the US FDA guidance, consisting of 2 eggs fried in butter, 2 strips of bacon, 2 slices of toast with butter, 4 ounces of hash brown potatoes, and 236 mL of whole milk. Fasted participants must fast for at least 10 hours prior to, and for at least 4 hours following, each dose of GRWD5769

Part B
a) an 800mg dose of GRWD5769 will be provided:

Sequence 1:
Treatment Period 1: 2 x 200 mg GRWD5769 capsules in the fed state followed by
Treatment Period 2: 1 x 400mg GRWD5769 tablets in the fed state

Sequence 2:
Treatment Period 1: 1 x 400mg GRWD5769 tablets in the fed state followed by
Treatment Period 2: 2 x 200 mg GRWD5769 capsules in the fed state.

b) there is a minimum 48 hours 'wash out' period between the fed/fasted assessments,
c) Participants will be observed when dosing to ensure adherence to dosage requirements.
Intervention code [1] 334007 0
Treatment: Drugs
Description of the comparator or control
There are 2 oral comparators for Part A and no control:
- 400 mg GRWD5769 Film Coated Tablet Formulation
- 200 mg GRWD5769 Capsule Formulation.

There are 2 comparators for Part B:
- Participants who have been feed a high fat meal prior to dosing with GRWD5769
- Participants who have fasted for 2 hours prior to taking GRWD5769
Control group
Active

Outcomes
Primary outcome [1] 345359 0
Part A – Bioavailability: To investigate the bioavailability of a GRWD5769 Film Coated Tablet Formulation relative to a GRWD5769 Capsule Formulation after single dose administration to fasted healthy adult participants
Timepoint [1] 345359 0
PK timepoints/collection: Pre-dose and up to 48 hours post-dose (0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48-hour timepoints)
Primary outcome [2] 345360 0
Part A – Bioavailability: To collect additional pharmacokinetic data for a GRWD5769 Film Coated Tablet Formulation and a GRWD5769 Capsule Formulation after single dose administration to fasted healthy adult participants including, but not limited to, Clast, Cmax, AUC 0-t, AUC 0-inf, AUC 0-24, T max, Kel, t 1/2, CL/F, V z/F, and ratios of C max and AUC between the GRWD5769 Film Coated Tablet Formulation and the GRWD5769 Capsule Formulation
Timepoint [2] 345360 0
PK timepoints/collection: Pre-dose and up to 48 hours post dose (0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48-hour timepoints)
Primary outcome [3] 345361 0
Part B – Food-effect: To investigate the food-effect on GRWD5769 after single dose administration to healthy adult participants under fed and fasted conditions via Plasma GRWD5769 concentrations, and to collect additional pharmacokinetic plasma data for GRWD5769 after single dose administration to healthy adult participants under fed and fasted conditions with Plasma pharmacokinetic parameters as determined by non-compartmental analysis including, but not limited to, Clast, Cmax, AUC 0-t, AUC 0-inf, AUC 0-24, T max, Kel, t 1/2, CL/F, V z/F, and ratios of C max and AUC between the GRWD5769 Film Coated Tablet Formulation and the GRWD5769 Capsule Formulation.
Timepoint [3] 345361 0
PK timepoints/collection: Pre-dose and post-dose for up to 48 hours (0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48-hour timepoints)
Secondary outcome [1] 461412 0
Part A – Bioavailability: (Composite Secondary Outcome) To investigate the safety and tolerability of a GRWD5769 Film Coated Tablet Formulation and a GRWD5769 Capsule Formulation after single dose administration to fasted healthy adult participants by assessing the frequency and severity of treatment emergent adverse events including clinically significant abnormal vital signs, 12-lead electrocardiograms, clinical laboratory test results, and physical examination findings will be assessed
Timepoint [1] 461412 0
At screening, pre-dose and throughout the study period and End of Study visit. - vital signs: Screening, Day -1, Pre-dose Day 1, 1hr post dose, 4 hr post dose, 8 hr post dose, 12 hr post dose, 24, 36 and 48 hr post dose, end of study visit. - 12-lead electrocardiograms: Screening, Day -1, Pre-dose Day 1, 2, 12 and 24 hr post dose, end of study. - clinical laboratory test results (urine and blood samples): Screening, Day -1, 8 and 12 hr post dose and end of study. - physical examination: Screening, Day -1, and 24 hr post dose. - collection and recording of adverse events (participant reported and as observed by clinical research staff): from screening to the end of the study, form the signing of consent to study completion.
Secondary outcome [2] 461414 0
Part B - Composite Secondary Outcome: To investigate the safety and tolerability of GRWD5769 after single dose administration to healthy adult participants under fed and fasted conditions by assessing the frequency and severity of treatment emergent adverse events including clinically significant abnormal vital signs, physical examination, 12-lead electrocardiograms, clinical laboratory tests results, and physical examination findings will be assessed
Timepoint [2] 461414 0
Vital signs will be collected at Screening, Baseline, 1, 4, 8, 12, 24, 36, 48 hours post dose and End of Treatment visit. Physical exams will be conducted at screening, baseline, and 24 hours post-dose. 12-lead ECGs will be conducted at screening, baseline, pre-dose, 2 hours post dose, 12 hours post-dose, 24 hours post-dose, and at the End of Study Visit. Blood samples: collected Pre-dose and up to 48 hours (0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48-hour timepoints) Urine samples: collected 8 and 12 hours post dose. Adverse events: these will be collected throughout the duration of trial participation. Screening, baseline, pre-dose, at 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48 hours and End of Study Visit.
Secondary outcome [3] 461415 0
Urine GRWD5769 concentrations at 8 and 12 hours post-dose. Urine pharmacokinetic parameters of GRWD5769 including Aet1-t2, CAe, Fet1-t2, CFe, CLr, if deemed appropriate at 8 and 12 hours post-dose.
Timepoint [3] 461415 0
8 and 12 hours post dose.
Secondary outcome [4] 461416 0
Exploratory (Part B): To characterize the pharmacokinetics of acyl glucuronide (major metabolite of GRWD5769) after single dose administration to healthy adult participants under fed and fasted condition with Plasma pharmacokinetic parameters of acyl glucuronide (major metabolite of GRWD5769) including Cmax and AUC, if deemed appropriate pre-dose and up to 48 hours post-dose. Urine pharmacokinetic parameters of acyl glucaronide (major metabolite of GRWD5769) including Aet1-t2, CAe, Fet1-t2, CFe, CLr, if deemed appropriate
Timepoint [4] 461416 0
For acyl glucuronide: Pre-dose and up to 48 hours (0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48-hour timepoints)
Secondary outcome [5] 461417 0
Exploratory (Part B): To characterize the pharmacokinetics of potential metabolites of GRWD5769 after single dose administration to healthy adult participants under fed and fasted conditions via Plasma pharmacokinetic parameters of potential metabolites of GRWD5769 including Cmax and AUC, if deemed appropriate pre-dose and up to 48 hours post-dose. Urine pharmacokinetic parameters of potential metabolites of GRWD5769 including Aet1-t2, CAe, Fet1-t2, CFe, CLr, if deemed appropriate
Timepoint [5] 461417 0
8 and 12 hours post-dose, for Part B Treatment Period 2 only.

Eligibility
Key inclusion criteria
To be eligible for this study, a participant must meet all the following inclusion criteria:

1. Aged 18 to 65 years (inclusive) at the time of informed consent.

2. Able and willing to provide written informed consent after the nature of the study has been explained and prior to the commencement of any study procedures.

3. Able and willing to attend the necessary visits to the Clinical Research Unit (CRU) and comply with the requirements of the Protocol.

4. Willing to consume meals provided by the CRU.

5. At the discretion of the PI (or designee), in good general health, with no significant medical history, and have no clinically significant abnormalities on physical examination at Screening and/or before administration of GRWD5769 on Day 1 of Treatment Period 1.

6. Body mass index of at least 18.0 and no more than 32.0 kg/m2 and weight of at least 50 kg.

7. Nonsmoker and must not have used any nicotine-containing products (eg, cigars, cigarettes, vapes) within 2 months prior to Screening.

8. Clinical laboratory values within normal range at Screening and/or Day -1 of Treatment Period 1 as specified by the testing laboratory, unless deemed not clinically significant by the PI (or designee).

9. Not pregnant or breastfeeding, or willing to cease breastfeeding.

10. Female participants must be of non-childbearing potential ie, surgically sterilised (hysterectomy, bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before the screening visit) or post-menopausal (where post-menopausal is defined as no menses for 12 months without an alternative medical cause and if post-menopausal within the 6 months prior to the Screening visit a follicle-stimulating hormone [FSH] level consistent with post-menopausal status, per local laboratory guidelines), or, if of childbearing potential:

- Must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test within 24 hours prior to administration of GRWD5769 on Day 1 of Treatment Period 1.
- Must agree not to attempt to become pregnant.
- Must not donate ova from signing consent until at least 33 days (ie, 30 days + minimum of 5 × half-lives of GRWD5769) after the last dose of GRWD5769.
- If not exclusively in a same sex relationship, must agree to use adequate contraception (which is defined as use of a condom by the male partner combined with use of a highly effective method of contraception) from signing the consent form until at least 6 months after the last dose of GRWD5769.

Note: FSH testing is required at Screening for female participants who report as post-menopausal (where post-menopausal is defined as no menses for 12 months without an alternative medical cause) if the female was determined to be post-menopausal within the 6 months prior to the Screening visit. Otherwise, and for females who are post-menopausal with no menses for at least 18 months, FSH testing is not required. If serum FSH levels are below the cut-off limit as defined by the local testing laboratory, participants will be considered to be of childbearing potential and will be required to use appropriate contraception for the duration of the study.

Note: A highly effective method of contraception is one that has a failure rate of < 1% when used consistently and correctly and for this study includes the following:

For Female Participants (of Childbearing Potential):
- Established use of oral, injected or implanted hormonal methods of contraception associated with inhibition of ovulation.
- Placement of an intrauterine device (IUD) or intrauterine system (IUS).
- Vasectomised partner (ie, a female participant’s male partner has undergone effective surgical sterilisation [ie, documented azoospermia at least 90 days after the procedure] before the female participant entered the study and he is the sole sexual partner of the female participant during the study).
- Abstinence from heterosexual intercourse (acceptable only if it is the participant’s usual form of birth control/lifestyle choice).

Examples of non-acceptable methods of contraception include:
- Condoms alone or double barrier.
- Periodic abstinence (eg, calendar, ovulation, symptothermal, post ovulation).
- Withdrawal.

Male participants must:
- Agree not to donate sperm from the time of signing consent until at least 93 days (90 days + minimum of 5 × half-lives of GRWD5769) after the last dose of GRWD5769.
- If engaging in sexual intercourse with a female partner who could become pregnant, must agree to use a condom plus a highly effective method of contraception from the time of signing consent until at least 93 days after the last dose of GRWD5769.

Note: A highly effective method of contraception is one that has a failure rate of less than 1% when used consistently and correctly and for this study includes the following:

For Female Partners (Who Are of Childbearing Potential) of Male Participants:
- Established use of oral, injected or implanted hormonal methods of contraception associated with inhibition of ovulation.
- Placement of an IUD or IUS.
- Vasectomised partner (ie, the male participant has undergone effective surgical sterilisation before entering the study).
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
A participant who meets any of the following exclusion criteria must be excluded from the study:

1. Underlying physical or psychological medical condition that, in the opinion of the PI (or designee), would make the participant unlikely to comply with the protocol or complete the study per protocol.

2. Blood or plasma donation or had significant blood loss (more than 500 mL) within 30 days prior to administration of GRWD5769 on Day 1 of Treatment Period 1.

3. Fever (body temperature at or greater than 38°C) or symptomatic viral or bacterial infection within 2 weeks prior to Screening.

4. Infections requiring parenteral antibiotics within 6 months prior to Screening.

5. Known medical history of infection or risk factors for human immunodeficiency virus (HIV) and/or hepatitis B or C infection.

6. History of life-threatening infection (eg, meningitis).

7. Vaccination with a live vaccine within 4 weeks prior to administration of GRWD5769 on Day 1 of Treatment Period 1 or vaccination with a non-live vaccine within 14 days prior to administration of GRWD5769 on Day 1 of Treatment Period 1.

8. Poor pill swallowing ability.

9. History of severe allergic or anaphylactic reactions, or sensitivity to GRWD5769 or its constituents.

10. History of malignancy, except for non-melanoma skin cancer, excised more than 2 years ago and cervical intraepithelial neoplasia that has been successfully cured more than 5 years prior to Screening.

11. Abnormal ECG findings at Screening, Day -1 and/or Day 1 (pre-dose) that are considered by the PI (or designee) to be clinically significant including:
- Mean QT interval corrected by Fridericia’s formula (QTcF) > 450 ms for males at both Screening and prior to administration of GRWD5769 on Day 1 of Treatment Period 1.
- Mean QTcF > 470 ms for females at both Screening and prior to administration of GRWD5769 on Day 1 of Treatment Period 1.
- Any clinically important abnormalities in rhythm, conduction, or morphology on resting ECG (eg, complete left bundle branch block, third degree heart block).
- Any factor that in the opinion of the PI (or designee) increases the risk of QTc prolongation or arrythmic events.

Note: The mean of triplicate readings (taken within 10 minutes with each reading separated by 1 to 5 minutes) will be used to determine eligibility.

13. History or presence of a condition associated with significant immunosuppression.

14. Exposure to any drugs that cause significant immunosuppression (including experimental therapies as part of a clinical study) within 4 months or 5 half-lives (whichever is longer) prior to Screening.

15. ALP, AST, and ALT > 1.5 × ULN at Screening.

16. Positive toxicology screening panel (urine test including qualitative identification of barbiturates, tetrahydrocannabinol [THC], amphetamines, benzodiazepines, opiates, and cocaine) or alcohol breath test.

17. History of substance abuse or dependency or history of recreational intravenous (IV) drug use over the last 5 years (by self-declaration).

18. Regular alcohol consumption defined as > 10 standard drinks per week (where 1 standard drink = 360 mL of beer, 45 mL of 40% spirit or a 150 mL glass of wine) or > 4 standard drinks on any single day.

19. Unwilling to abstain from alcohol from 48 hours prior to admission to the CRU through to the EOS Visit.

20. Use of any investigational medical device or investigational drug within 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to administration of GRWD5769 on Day 1 of Treatment Period 1.

Note: Participants who plan to complete Day 1 of Treatment Period 1 at least 48 hours after the last dose administration of GRWD5769 (to maintain a minimum 48-hour washout) are permitted to enrol in Part A2 (Bioavailability – 400 mg GRWD5769) (if applicable) and/or Part B (Food-effect).

21. Use of any prescription drugs (other than hormonal contraception; oral contraceptive pills, long-acting implantable hormones, injectable hormones, a vaginal ring, or an IUD), over-the-counter medication, herbal remedies, supplements or vitamins within 30 days prior to administration of GRWD5769 on Day 1 of Treatment Period 1 or anticipated use during the course of the study without prior approval of the PI (or designee) and Novotech MM.

Note: Simple analgesia (paracetamol, nonsteroidal anti-inflammatory drug [NSAID]) may be permitted at the discretion of the PI (or designee).

22. Use of any strong inhibitors or inducers of CYP3A4 including medications, herbal supplements (eg, St John’s wort) within 30 days prior to administration of GRWD5769 on Day 1 of Treatment Period 1 or anticipated use during the course of the study.

23. Use of any prescription or non-prescription medication (including herbal remedies, vitamins, and nutritional supplements) that are potential CYP3A4 substrates or may be affected by Breast Cancer Resistance Protein (BCRP) / Organic Anion Transporting Polypeptide (OATP) 1B1 / B3 hepatic uptake sensitivity within 30 days prior to administration of GRWD5769 on Day 1 of Treatment Period 1 or anticipated use during the course of the study.

24. Use of any food or drinks that are strong inhibitors or inducers of CYP3A4 (eg, grapefruit juice, pomegranate, starfruit or pomelo) within 14 days prior to administration of GRWD5769 on Day 1 of Treatment Period 1 or anticipated use during the course of the study without prior approval of the PI (or designee) and Novotech MM.

25. Unwilling to refrain from strenuous exercise (including weightlifting) from 48 hours prior to admission to the CRU and through to the EOS Visit.

26 Anything that the PI (or designee) considers would jeopardise the safety of the participant, prevent complete participation in the study, or compromise interpretation of study data.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The Study Biostatistician will generate a randomisation list for each study part. Once deemed eligible for enrolment in the study, the participant will be assigned a sequential randomisation number prior to administration of GRWD5769 on Day 1
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Bio-availability
Statistical methods / analysis
In general, descriptive statistics (e.g., arithmetic mean, standard deviation [SD], median, minimum, and maximum) are to be calculated for continuous data by treatment and protocol-specified time point, while frequency summaries (e.g., number of observed and percentage of each category) are to be applied for categorical data by treatment and protocol-specified time point.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment postcode(s) [1] 45815 0
4558 - Maroochydore

Funding & Sponsors
Funding source category [1] 321810 0
Commercial sector/Industry
Name [1] 321810 0
Greywolf Therapeutics
Country [1] 321810 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Greywolf Therapeutics
Address
Country
Australia
Secondary sponsor category [1] 324662 0
None
Name [1] 324662 0
Address [1] 324662 0
Country [1] 324662 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320355 0
Bellberry Human Research Ethics Committee
Ethics committee address [1] 320355 0
Ethics committee country [1] 320355 0
Australia
Date submitted for ethics approval [1] 320355 0
20/05/2026
Approval date [1] 320355 0
18/06/2026
Ethics approval number [1] 320355 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150198 0
Dr Christopher Moller
Address 150198 0
University of the Sunshine Coast Clinical Trials (Maroochydore), Maroochy Private Hospital, 12 Future Way, Maroochydore, QLD 4558
Country 150198 0
Australia
Phone 150198 0
+61 07 5459 4446
Fax 150198 0
Email 150198 0
Contact person for public queries
Name 150199 0
Mara Giovannetti
Address 150199 0
Greywolf Therapeutics Pty, Suite 201/697 Burke Road, Camberwell, VIC, 3124
Country 150199 0
Australia
Phone 150199 0
+61 419507574
Fax 150199 0
Email 150199 0
Contact person for scientific queries
Name 150200 0
Allen Zhong
Address 150200 0
Novotech CRO, Level 13/440 Collins St, Melbourne VIC 3000
Country 150200 0
Australia
Phone 150200 0
+61 02 8569 1499
Fax 150200 0
Email 150200 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.